Recently, the "15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference," also known as the Qisihui Conference, was held in Hangzhou. The event was organized by the China Association of Pharmaceutical Commerce, China Association of Pharmaceutical Biotechnology, Hangzhou Investment Promotion Bureau, and Hangzhou Linping District Bureau of Commerce. It was co-hosted by Healthcare Executive and the China Medical and Health Industry Investment 50 Forum. During the conference, the "Top 100 Best in China Pharmaceutical Innovation Value Discovery" for the year 2022-2023 was announced. Leman Biotech was successfully selected for its project "AI Empowered Metabolically Enhanced Immunotherapy."
This event aims to promote the R&D innovation translation in the Chinese pharmaceutical industry. During the Qisihui Conference, Healthcare Executive established the "LinkValue Leading Innovation Docking Platform" and invited industry leaders, experts, investors, and Bigpharma BD to evaluate projects based on four dimensions: technological innovation, degree of translational application, market prospects, and R&D team. From numerous projects, the "Top 100 Best in China Pharmaceutical Innovation Value Discovery" were selected.
The emergence of original innovative drugs relies on the support of basic research and translational medicine. Meanwhile, the development of basic research and translational medicine is crucial for propelling China's pharmaceutical innovation towards originality. Leman Biotech's inclusion is a renewed recognition by expert reviewers of the company's work in original research on metabolic reprogramming technology and Meta 10 platform developed on this basis. The metabolically enhanced CAR-T cell therapy developed on this platform has achieved complete remission in over ten patients in Investigator-Initiated Trials (IIT) clinical studies.
In the future, Leman Biotech will continue to strengthen R&D and translational efforts, leveraging AI in CAR-T development to enhance its technical expertise and innovation capabilities. The goal is to provide patients with safer and more effective treatment options, driving the high-quality development of China's biopharmaceutical industry towards original innovation.
